Gamma‐oryzanol for behavioural and psychological symptoms of dementia

Fujii, Masahiko; Butler, James P.; Sasaki, Hidetada

doi:10.1111/psyg.12303

Cited by 9 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, ORY is recognized as a good dietary supplement and a pharmaceutical candidate for the maintenance and enhancement of human health during ageing [15]. Thanks to its lipophilic characteristics, ORY passes through the blood-brain barrier and exerts effects even in the central nervous system (CNS) [16]. For example, in mouse models of anxiety and stress, Kozuka and colleagues demonstrated that ORY exerted its therapeutic effects by modulating dopamine receptor 2 [17].…”

Section: Introductionmentioning

confidence: 99%

Gamma-oryzanol Prevents LPS-induced Brain Inflammation and Cognitive Impairment in Adult Mice

et al. 2019

View full text Add to dashboard Cite

Background: Rice (Oryza sativa L.) is the main food source for more than half of humankind. Rice is rich in phytochemicals and antioxidants with several biological activities; among these compounds, the presence of γ-oryzanol is noteworthy. The present study aims to explore the effects of γ-oryzanol on cognitive performance in a mouse model of neuroinflammation and cognitive alterations. Methods: Mice received 100 mg/kg γ-oryzanol (ORY) or vehicle once daily for 21 consecutive days and were then exposed to an inflammatory stimulus elicited by lipopolysaccharide (LPS). A novel object recognition test and mRNA expression of antioxidant and neuroinflammatory markers in the hippocampus were evaluated. Results: ORY treatment was able to improve cognitive performance during the neuroinflammatory response. Furthermore, phase II antioxidant enzymes such as heme oxygenase-1 (HO-1) and NADPH-dehydrogenase-quinone-1 (NQO1) were upregulated in the hippocampi of ORY and ORY+LPS mice. Lastly, γ-oryzanol showed a strong anti-inflammatory action by downregulating inflammatory genes after LPS treatment. Conclusion: These results suggest that chronic consumption of γ-oryzanol can revert the LPS-induced cognitive and memory impairments by promoting hippocampal antioxidant and anti-inflammatory molecular responses.

show abstract

Section: Introductionmentioning

confidence: 99%

Gamma-oryzanol Prevents LPS-induced Brain Inflammation and Cognitive Impairment in Adult Mice

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, we didn’t use HRT as a drug control because the ethics committee considered that it might be carcinogenic to peri-menopausal women. Oryzanol is a kind of autonomic agent, which is widely used in the adjuvant treatment of insomnia, anxiety and depression in peri-menopausal women ( Fujii et al, 2018 ). The mechanism study shows that oryzanol can increase the release of catecholamine related relatives in limbic system through the blood-brain barrier, which may be related to the improvement of stress ( Fujii et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

“…Oryzanol is a kind of autonomic agent, which is widely used in the adjuvant treatment of insomnia, anxiety and depression in peri-menopausal women ( Fujii et al, 2018 ). The mechanism study shows that oryzanol can increase the release of catecholamine related relatives in limbic system through the blood-brain barrier, which may be related to the improvement of stress ( Fujii et al, 2018 ). In addition, some studies have found that oryzanol also has anti-inflammatory and antioxidant effects ( Minatel et al, 2016 ; Ramazani et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy, safety and mechanism of Honghua Xiaoyao Pill in the treatment of peri-menopausal syndrome: A study protocol for a randomized controlled trial

Zhou

Dong

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Peri-menopausal syndrome (PMPS) has a high incidence rate and seriously affects the physical and mental health of women. Honghua Xiaoyao Pill (HHXYP) is a Chinese patent medicine, which has been reported to be used to treat PMPS. However, there is still a lack of randomized clinical trial to evaluate the efficacy and safety of HHXYP on life quality, mood and vasomotor symptoms for PMPS women. This study aims to investigate whether HHXYP is effective and safe in treating PMPS and the possible mechanism.Methods: A multicenter, randomized, controlled clinical trial will be conducted in China to evaluate the efficacy and safety of HHXYP. Sixty women with peri-menopausal syndrome will be recruited at three centers and randomly in a 1:1 ratio to a treatment group using HHXYP (HHXYP group) and a control group using oryzanol (OC group). Participants will be treated with HHXYP or oryzanol for 12 weeks and followed up for 4 weeks. The primary outcome is the modified Kupperman Index (KI), which will be measured at baseline and 4, 8, 12, 16 weeks after randomization. The secondary outcomes include Hot flash scale (HFs), Menopause-Specific Quality of Life Scale (MENQOL) and Hamilton Depression/Anxiety Scale (HAMD/HAMA). The HFs are measured at the same point as the KI, other secondary outcomes are measured at baseline and 12, 16 weeks after randomization. The other outcomes are the levels of serum sex hormone, monoamine neurotransmitter, vascular vasomotor factor and the expression of phosphatidylinositol 3-active enzyme (PI3K)/protein activator enzyme B (Akt), which will be measured at baseline and 12 weeks after randomization. Adverse events will also be reported.Discussion: HHXYP is a potential alternative Chinese patent medicine for PMPS. This trial will provide evidence for HHXYP on improving the quality of life, mood and vasomotor symptoms, and sex hormone levels of PMPS patients.

show abstract

“…Psychotropics included antipsychotics, anxiolytics, antidepressants, anti‐epileptics, the Chinese medicine Yi‐Gan San, gamma‐oryzanol, and tiapride. Antipsychotic tablets used were chlorpromazine (from 12.5 mg to 25 mg), and levomepromazine (5 mg), risperidone (from 1 mg to 3 mg), olanzapine (from 5 mg to 10 mg), and quetiapine fumarate (from 25 mg to 75 mg).…”

Section: Methodsmentioning

confidence: 99%

Antipsychotic drug use and favourable natures of emotional functions in patients with dementia

2019

Self Cite

View full text Add to dashboard Cite

Aim To characterise the effects of antipsychotics on brain functions of patients with behavioural psychological symptoms of dementia (BPSD). Methods Studies were performed during 6 weeks of intervention with either a nonantipsychotic drug (group A, n = 38) or an antipsychotic drug (group B, n = 10). Results Neuropsychiatric Inventory scores were significantly decreased in both groups. Scores on the Mini‐Mental State Examination did not change with intervention. By contrast, favourable natures of emotional functions, scored using the Delightful Emotional Index of 10 items, were significantly lower in the antipsychotic drug treatment group B relative to scores in the nonantipsychotic drug treatment group A. Conclusions Antipsychotics reduce favourite emotions as well as BPSD, and this should be considered in prescribing medications for patients with dementia.

show abstract

Gamma‐oryzanol for behavioural and psychological symptoms of dementia

Cited by 9 publications

References 4 publications

Gamma-oryzanol Prevents LPS-induced Brain Inflammation and Cognitive Impairment in Adult Mice

Gamma-oryzanol Prevents LPS-induced Brain Inflammation and Cognitive Impairment in Adult Mice

Efficacy, safety and mechanism of Honghua Xiaoyao Pill in the treatment of peri-menopausal syndrome: A study protocol for a randomized controlled trial

Antipsychotic drug use and favourable natures of emotional functions in patients with dementia

Contact Info

Product

Resources

About